|
|
15 Adam Street
London, WC2N 6LA United Kingdom
phone:+44 (0)20 7401 7646
fax:+44 (0)20 7930 3353
|
|
| Symbol |
SNN |
| Exchange |
NYSE |
| Founded |
1856 |
| Employees |
7451 |
|
|
| www.smith-nephew.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Medical devices for orthopaedics, endoscopy and advanced wound management. |
|
| Management |
| David Illingworth, Chief Executive; Adrian Hennah, Chief Financial Officer; Elizabeth Bolgiano, Group Director Human Resources; Jack Campo, Chief Legal Officer; Joe Woody, President of Advanced Wound Management; Joseph M DeVivo, President Orthopaedic Reconstruction; Liz Hewitt, Group Director of Corporate Affairs; Mark Augusti, President Orthopaedic Trauma & Clinical Therapies; Michael Frazzette, Endoscopy President; Paul Chambers, Company Secretary and Group Compliance Officer; R. Gordon Howe, Senior Vice President Global Planning and Development; Sal Chiovari, Chief Information Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| orthopedics, spine, ortho joint, reconstruction, ortho joint, reconstruction, ortho, joint, reconstruction, advamed |
|
|
|
| Description |
|
Smith & Nephew develops and markets advanced medical devices that help healthcare professionals treat patients more effectively; and get patients get back to their normal lives faster. Their dedicated Global Business Units: Orthopaedics, Endoscopy and Advanced Wound Management specialize in innovative, cost-effective products that meet pressing healthcare needs. |
|
| Products / Services |
Smith & Nephew's three Global Business Units - Orthopaedics, Endoscopy and Advanced Wound Management - have worldwide responsibility for the research and development, manufacturing and marketing of their respective product ranges. They also have direct responsibility for sales in eight key countries. Together, they offer over 1,000 product ranges.
|
|
|
| Competitors / Substitutes / Alternatives |
Biomet Inc (BMET), DePuy Inc. and Stryker Corp (SYK).
|
|
| Status |
| In the last quarter of 2004, the company expects to deliver strong growth, capitalising on their recent investment in sales forces and new products. Market fundamentals continue to be favourable. They expect both Orthopaedics and Endoscopy to benefit from a seasonally stronger last quarter. The company has strong momentum going into 2005, which should see them achieving high teens sales growth at Orthopaedics and high single digit growth at Endoscopy and Wound Management next year. They also plan further margin improvements. They are thus well placed to sustain their underlying mid-teens EPSA growth target from this year into next. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
